Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor
Ontology highlight
ABSTRACT: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitors have been approved for treating renal anemia, yet have failed clinical testing for inflammatory bowel disease (IBD) due to lack of efficacy. We use a multimodel multimodal generative AI platform to design an orally gut-restricted selective PHD1/2 inhibitor, which exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.
INSTRUMENT(S): Q Exactive
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Colon
SUBMITTER: Chenxi Xu
LAB HEAD: Yanyun Fu
PROVIDER: PXD057486 | Pride | 2024-12-12
REPOSITORIES: Pride
ACCESS DATA